SCPHARMACEUTICALS ($SCPH) is expected to release its quarterly earnings data on Wednesday, March 19th after market close, per Finnhub. Analysts are expecting revenue of $12,325,680 and earnings of -$0.39 per share.
You can see Quiver Quantitative's $SCPH stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SCPHARMACEUTICALS Hedge Fund Activity
We have seen 47 institutional investors add shares of SCPHARMACEUTICALS stock to their portfolio, and 48 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY added 1,577,434 shares (+474.2%) to their portfolio in Q4 2024, for an estimated $5,584,116
- UBS GROUP AG added 1,017,775 shares (+5218.3%) to their portfolio in Q4 2024, for an estimated $3,602,923
- AWM INVESTMENT COMPANY, INC. removed 764,857 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,707,593
- KING LUTHER CAPITAL MANAGEMENT CORP added 632,120 shares (+28.4%) to their portfolio in Q4 2024, for an estimated $2,237,704
- CITADEL ADVISORS LLC removed 525,964 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,861,912
- VELAN CAPITAL INVESTMENT MANAGEMENT LP removed 517,668 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,832,544
- PERCEPTIVE ADVISORS LLC added 500,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $1,770,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SCPHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $SCPH in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 12/02/2024
- Cowen & Co. issued a "Buy" rating on 10/23/2024
To track analyst ratings and price targets for SCPHARMACEUTICALS, check out Quiver Quantitative's $SCPH forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
